1. Home
  2. ICHR vs CAPR Comparison

ICHR vs CAPR Comparison

Compare ICHR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ichor Holdings

ICHR

Ichor Holdings

HOLD

Current Price

$72.92

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$29.40

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICHR
CAPR
Founded
1999
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2016
2011

Fundamental Metrics

Financial Performance
Metric
ICHR
CAPR
Price
$72.92
$29.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
8
Target Price
$49.50
$44.63
AVG Volume (30 Days)
1.0M
1.1M
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$947,652,000.00
N/A
Revenue This Year
$20.51
N/A
Revenue Next Year
$17.08
$3.31
P/E Ratio
N/A
N/A
Revenue Growth
11.61
N/A
52 Week Low
$13.15
$4.30
52 Week High
$78.00
$40.37

Technical Indicators

Market Signals
Indicator
ICHR
CAPR
Relative Strength Index (RSI) 59.23 44.84
Support Level $16.51 $27.98
Resistance Level $72.87 $30.06
Average True Range (ATR) 4.47 1.72
MACD -0.97 -0.27
Stochastic Oscillator 67.12 35.32

Price Performance

Historical Comparison
ICHR
CAPR

About ICHR Ichor Holdings

Ichor Holdings Ltd designs, engineers, and manufactures critical fluid delivery subsystems and components mainly for semiconductor capital equipment, along with solutions for defense/aerospace and medical industries. Its product portfolio includes gas and chemical delivery subsystems that enable precise delivery, monitoring, and control of specialized gases and reactive liquid chemistries used in semiconductor manufacturing processes such as etch, electroplating, and cleaning. The company also provides precision-machined components, weldments, e-beam and laser-welded components, as well as precision vacuum and hydrogen brazing. Geographically, the company operates across the United States, Singapore, Europe, and other regions, with Singapore contributing the majority of revenue.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: